![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
pharma mystery
I don't understand the drug industry. Ok, ok, nobody does. Let me be more specific: I don't understand what's going on with one of my glaucoma drugs, Xalatan.
This drug has been on the market since 1996 without a generic option, meaning it costs more than $100 a month if you pay for it yourself (which of course most people don't, but delving into insurance-based pricing in this post would be scope creep). My co-pay is higher for a name-brand drug than for a generic, so I have personal interest in this going generic.
About a year ago word on the street was that the patent was due to expire last September, but something seems to have happened because it's now, according to the patent office, locked in until early 2011. According to my doctor, some insurance companies are applying pressure to ophthamologists, pushing them to use different drugs instead to treat this condition because of the expense. One way or another, it appears that Pfizer has about another year to collect the big bucks from customers before they have to accept that a 15-year monopoly is a pretty good run.
Given all that, I was surprised at this morning's checkup to receive not only a free sample (a month's supply) but also a card that I can use four times or up to $350, whichever comes first, getting my prescription filled. So my next four bottles of the stuff will be free. Before I use that up I'll have another checkup, at which I might score another freebie and perhaps another card. Even if the promotion is over by then, they'll have given up four months' worth of monopoly pricing on me in their final year of being guaranteed to collect it.
How is this in their interest? I'm happy to pocket the savings; I've been pouring money into keeping my glaucoma at bay for as long as I've been paying my own bills. (It was diagnosed when I was a child.) But I don't understand why I'm getting these savings at this time.
This drug has been on the market since 1996 without a generic option, meaning it costs more than $100 a month if you pay for it yourself (which of course most people don't, but delving into insurance-based pricing in this post would be scope creep). My co-pay is higher for a name-brand drug than for a generic, so I have personal interest in this going generic.
About a year ago word on the street was that the patent was due to expire last September, but something seems to have happened because it's now, according to the patent office, locked in until early 2011. According to my doctor, some insurance companies are applying pressure to ophthamologists, pushing them to use different drugs instead to treat this condition because of the expense. One way or another, it appears that Pfizer has about another year to collect the big bucks from customers before they have to accept that a 15-year monopoly is a pretty good run.
Given all that, I was surprised at this morning's checkup to receive not only a free sample (a month's supply) but also a card that I can use four times or up to $350, whichever comes first, getting my prescription filled. So my next four bottles of the stuff will be free. Before I use that up I'll have another checkup, at which I might score another freebie and perhaps another card. Even if the promotion is over by then, they'll have given up four months' worth of monopoly pricing on me in their final year of being guaranteed to collect it.
How is this in their interest? I'm happy to pocket the savings; I've been pouring money into keeping my glaucoma at bay for as long as I've been paying my own bills. (It was diagnosed when I was a child.) But I don't understand why I'm getting these savings at this time.
no subject
And as someone else already said, not all generics are actually equivalent to their name-brand inspiration... We ran into that with one of my kids' meds and had a brief fight with the insurance co until the prescribing doc got on our side and signed on the "brand-name specified" line of the script each time.
no subject
no subject